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Alveolar echinococcosis (AE) is a neglected ‘malignant’ parasitic disease. The European 24 
endemic area of Echinococcus multilocularis in foxes is larger than previously 25 
anticipated and there is new evidence that fox populations and E. multilocularis 26 
prevalences have increased in many areas, implicating an increased infection pressure 27 
with E. multilocularis eggs for intermediate and aberrant hosts, including humans.  This 28 
may result in more human AE cases within the next decades. Current numbers of both 29 
immunocompetent and immunocompromised AE patients and anticipated future 30 
developments call for scaling up research to rapidly improve the development and 31 
respective implementation of prevention, early diagnosis and curative treatment of 32 
human AE. 33 
 34 
Infection dynamics, disease burden and health economic considerations  35 
Despite excellent public health systems, alveolar echinococcosis (AE), a zoonosis due to infection 36 
with the larval form of the fox tapeworm E. multilocularis [1] , is expanding in Europe (Figure 1) 37 
[2,3]. For many decades, E. multilocularis infection in definitive hosts (predominantly foxes) 38 
(Figure 1), and thus also AE, a silently progressing hepatic disorder in humans, was largely 39 
restricted to a defined region of Central Europe. Over the past two decades, intensive 40 
epidemiological research revealed significant expansion into Northern, Eastern and Western 41 
Europe (Figure 2). Emergence of E. multilocularis endemicity in fox populations has been 42 
confirmed in many European countries, including the Baltic States, Poland, Slovakia, Romania 43 
and Slovenia. Furthermore, countries previously documented to be free of E. multilocularis (e.g. 44 
the United Kingdom, Ireland, Malta, Norway, Finland) are taking great efforts to assess the risk 45 
of introducing E. multilocularis into their countries through imported dogs and wildlife animals 46 
[4]. Increased traffic of pet dogs and relocation of wildlife have already sporadically contributed 47 
to the spread of this zoonosis  [5]. AE has even become a threat in primates of several European 48 
zoos [6,7] and breeding enclosures [8]. In Central Europe, expanding red fox populations and 49 
colonization of residential areas are a major factor for a significant increase of the infection risk 50 
[9-12]. With a time delay of 10-15 years, such changes in definitive host ecology can lead to an 51 
increase in the incidence of human AE cases as already documented in some areas [13-17]. 52 
Across the total population of endemic countries such as France, Germany, Austria and 53 
Switzerland, AE is considered as a rare disease with average incidences of 0.03 to 0.30/100,000 54 
inhabitants/year. These numbers, however, do not reflect the situation of the actual population 55 
at risk; far higher incidences, from 4.7 to 8.1 cases per 100,000 inhabitants/years are observed 56 
in nested clusters of E. multilocularis infection in the same countries [15,15]. Several studies 57 
found a recent upward trend in incidence [13-16]: in Switzerland, for example, an average 58 
twofold increase of the annual incidence was reported between the periods 1993-2000 and 59 
2001-2005 [13]. Observations in France and Austria revealed similar trends [14,16]. In some of 60 
the countries of Eastern-Central Europe, which were not considered to be endemic areas, a 61 
steady but limited increase in number of human cases has been observed [18,19], and in the 62 
Baltic countries, such as Lithuania, a tenfold increase of the AE-incidence was reported in 2009-63 
2012, and the incidence ranged from 0.03 in 1997-2002 to 0.5-0.77 in 2009-2012 per 100,000 64 
inhabitants [20]. Such trends all over Europe may not only be due to the  increase in infection 65 
potential but also other causes, e.g. to the growing number of patients under 66 
immunosuppressive therapy with a significantly higher risk of developing AE [21,22]. In the new 67 
endemic areas such as the Baltic region, awareness of the disease and improved diagnostics may 68 
have contributed to the increase of AE cases registered. Conversely, in historically endemic areas 69 
of Western-Central Europe, where ultrasound and CT-scans have been widely available since the 70 
end 1970s, no alterations in the severity of liver infections, or in the rate of radical surgery cases 71 
have been observed in the last decades in immunocompetent AE patients [13,23]. In France, 72 
asymptomatic cases were shown in the 1980s, as a result of the systematic use of ultrasound 73 
(19% of patients not diagnosed by mass screening were asymptomatic at the time of diagnosis 74 
in the 1983-1993 period compared with 9% in the 1972-1982 period) [24], and the ratio of 75 
symptomatic/asymptomatic cases, as shown from the systematic recording of cases in a 76 
dedicated registry, was stable [25,26]. These facts indicate that the increase of incidence in 77 
Western-Central Europe is not primarily based on an earlier diagnosis. One known parameter 78 
that accounts for an annual increase in AE cases  includes those patients with immune 79 
suppression who were subsequently found with AE: earlier diagnosis in these patients could be 80 
partially due to better recognition of AE as these patients were already receiving medical 81 
attention because of their primary underlying disease (cancer, chronic inflammatory disorders), 82 
or because these patients also present faster progression of AE [22]. 83 
 84 
High environmental contamination pressure for intermediate hosts is also illustrated by the 85 
occurrence of AE in accidental/aberrant intermediate hosts that usually do not take part in the 86 
parasite cycle, such as dogs, pigs and primates [2,6,7,27]. 87 
 88 
Globally, AE causes an annual loss of approximately 660,000 disability-adjusted life years as 89 
determined in 2008 [28]. In terms of new cases, it may be estimated that Central, North and 90 
Southeastern Europe together might in the near future face close to 1,000 new cases per year, 91 
as extrapolated from data of the Central European highly endemic area1; these regions may not 92 
yet have reached a plateau, because of the geographical extension of fox infection, and in new 93 
endemic areas transmission rates will likely continue to increase for several years, as anticipated 94 
for the Netherlands [29]. As determined in 2008, the costs per AE patient in Europe yields a 95 
mean of € 110,000 [28]. This is due to the fact that too many patients continue to present at 96 
advanced disease stages, necessitating life-long chemotherapy, complex interventions 97 
(endoscopic, liver surgery), or, as a last resort, liver transplantation [24,26,28,30]. Prolonged 98 
survival of the population in general and of AE patients in particular may increase this cost in the 99 
                                                
1 The accumulated population size of all AE‐affected countries (Figure 1) were derived from 
<http://en.wikipedia.org/wiki/List_of_European_countries_by_population> and yielded 290 million 
inhabitants. Extrapolation was based on Swiss data and is as follows: 28 new annual cases divided by 8 
(Switzerland) and multiplied by 290 (Europe) = 1015. 
future. If early detection and treatment options do not make progress beyond current practices, 100 
based on current Swiss and French estimations of cost per patient that will be reached by most 101 
of European countries in a near future, Europe could well face costs in the range of one (or 102 
more) billion(s) € 2 to care for the numbers of AE patients to be expected in 10-20 years. 103 
 104 
Control problems 105 
The very nature of the life cycle of AE, with predominantly wildlife as intermediate (rodents) and 106 
definitive (fox) hosts, precludes eradication. So far, long-term baiting of foxes with appropriate 107 
medication is the most effective tool to locally decrease the environmental contamination and 108 
prevalence in wild hosts (and consequently in dogs as well) in a significant, although temporary, 109 
way [31]. However, the implementation of this approach strongly depends on public attitude, 110 
available financial resources and priority setting of political decision-makers. The European Food 111 
and Safety Authority (EFSA) realized the urgency of the problem and launched a project 112 
(GP/EFSA/AHAW/2012/01) to meta-analyze present surveillance data on E. multilocularis 113 
infection in animals. From currently available published literature and EU reports, the situation is 114 
clearly different in the various European countries, depending on the kind of national 115 
regulations and funding [2,9,10,29,32-38]. Information on epidemiological changes in animal 116 
populations may help to predict the emergence of AE in humans, and to take appropriate 117 
measures. In addition, E. multilocularis reproduces very well in domestic dogs as definitive hosts, 118 
and based on the high dog population in Europe, even a low average prevalence estimate (i.e. 119 
0.3% in Switzerland) [32]  can significantly contribute to environmental contamination by eggs, 120 
and to infection risk for humans [31,39]. Furthermore, dogs with particular infection risk (free 121 
roaming and with access to rodents) can reach remarkably high prevalence of infection with E. 122 
multilocularis [40]. A monthly deworming scheme for domestic dogs with access to rodents [32] 123 
represents an effective measure to reduce the risk of infection in humans, provided that an 124 
appropriate drug such as praziquantel is used. The European Scientific Counsel on Companion 125 
Animal Parasites (ESCCAP) has started informational campaigns in Europe [41]. An appropriate 126 
surveillance scheme at the EU level is, however, absolutely necessary to set up similar standards 127 
in the various member states and associated countries: it may be noted that the 2010 EU 128 
surveillance report [37]  does not always properly discriminate between E. multilocularis and E. 129 
granulosus, which precludes any precise knowledge of the respective epidemics in animals and 130 
of the incidence of the related –and notably different- diseases in humans. Several at-risk-131 
countries that do not belong to the European Union have no legal obligation to declare their 132 
cases to the European Centre for Disease Control (ECDC) and EFSA [37,38]; for instance, the 133 
2010 report [37] does not include data from Switzerland.  134 
Clinical problems 135 
                                                
2 1000 new AE cases per year (see footnote 1) = 10'000 new cases per 10 years multiplied by 110'000 € = 
1'100'000'000 €. 
Due to the malignant nature with infiltrative growth and metastatic spread characteristics of the 136 
metacestode tissue that clinically behaves like a tumour, AE can principally cause premature 137 
death in advanced stages, especially if remaining untreated or improperly treated. In Europe 138 
(and some other endemic regions), thanks to life-long administration of benzimidazoles in those 139 
patients who cannot benefit from radical surgical resection of the lesions, i.e. two third of 140 
patients, it has become a chronic disease, with far less threat to their life than 30 years ago but 141 
significant impairment of quality of life’ [26,28,30,42,43]. Numerous types of complications do 142 
occur in these patients, including e.g. biliary obstruction with jaundice, septicemia due to 143 
repeated cholangitis and bacterial infection of necrotic cavities in the lesion, portal hypertension, 144 
chronic Budd-Chiari disease, among many others [24,26,42,44] Compared to cancers with 145 
similar incidence (http://www.rarecancerseurope.org), AE receives, from the clinical point of 146 
view, appallingly little attention. Currently, treatment options for AE are few. Surgery is reserved 147 
for early stage treatment when lesions can be completely resected with a safe margin of 148 
unaffected tissue and no distant metastases [44]. Advanced cases may be only saved by surgical 149 
ventures, such as major palliative surgery or liver transplantation, requiring appropriate 150 
infrastructures and surgical experiences [45]  Drug treatment for all other cases has its own 151 
limitations. Only two closely related drugs (albendazole and mebendazole), which are not always 152 
available, can be used to treat AE and significantly contributed, in the last decades, to a 153 
relevantly longer survival of AE patients as compared to the situation prior to drug treatment 154 
[23,24,28,44]. Nevertheless, they rarely kill E. multilocularis and thus life-long treatment is 155 
required to inhibit or at least suppress parasite growth in AE patients who could not benefit 156 
from radical surgery [44]. Some patients do not tolerate these compounds because of hepato- 157 
and/or hemato-toxicity [44,46]. Studies to precisely assess the proportion of patients who 158 
cannot be treated by the drug because of adverse effects are in need. This proportion seems to 159 
be higher in patients suffering immune suppression due to a pre-existing condition and 160 
associated treatments [22]. In addition, these drugs cannot be used during pregnancy, with a 161 
risk of even faster progression of AE in pregnant patients [47]. The increased incidence of AE in 162 
young adults in recent years has made the management of the disease in women of 163 
childbearing age problematic. 164 
 165 
Present challenges and future perspectives 166 
 167 
The anticipated increase in number of human AE cases in Europe within the next decades call 168 
for scaling up research in key areas such as prevention, early diagnosis and curative treatment of 169 
human AE, among others. 170 
 171 
Management of clinical AE cases  172 
The cancer-like growth behavior of E. multilocularis larvae has been stressed, which requires 173 
staging and stage-based multidisciplinary clinical management of AE, as it is now for cancer 174 
[48]. In cancer care management, tremendous progress has been made through centre-based 175 
care, in particular in rarer forms of malignancies. Shared experiences between oncologists and 176 
AE-specialists can effectively be translated into clinical decision-making. In particular, various 177 
imaging modalities to improve AE diagnosis and staging, radical surgery to achieve cure also in 178 
advanced disease, as recently proposed but not evaluated [45,49], psychosocial programs and 179 
long-term care bear potential for cross fertilization from cancer to AE.  180 
Based on the long-term clinical experience of Swiss, French and German clinical AE centers, 181 
standardized AE diagnosis and treatment protocols can be developed, validated and 182 
disseminated. Networking with reference centers in AE-endemic countries including Baltic and 183 
Central-Eastern European countries is essential to meet the threat of increasing numbers of AE 184 
patients and to achieve commonly agreed standards. Specific immunological tests (such as e.g. 185 
Em18 and Em2-ELISAs, and Immunoblotting; reviewed in [44]) in combination with high-186 
performance imaging techniques promise substantial improvements in early diagnosis, essential 187 
for curative treatment, as well as in staging and follow-up of patients. Furthermore, 188 
standardized registration and follow-up protocols are essential to properly assess the 189 
epidemiology of the disease and its trends in all European countries, and to prepare the ground 190 
for multi-centric clinical trials to formally test new treatment options. So far, a population-based 191 
publicly-funded registry, designed on the model of the Cancer Registries, only exists in France 192 
with a satisfactory level of exhaustivity [15,26,50]. Mandatory notification, at least as it is 193 
organized in Germany, has proved to be inefficient [51]; academic reports have stressed that 194 
many published AE cases were not recorded by the national notification system [9]. An extended 195 
patient registry at the full European level would not only significantly contribute to improve the 196 
clinical management of AE, but also to better delineating areas and populations at risk to test 197 
new prevention strategies, and in promoting disease awareness in these populations [10,39] 198 
[15,52] .  199 
 200 
Chemotherapy of AE cases: a huge place for improvement  201 
Chemotherapy currently relies on albendazole and mebendazole, but there is clearly a need for 202 
improvement. The availability of the E. multilocularis genome sequence and comprehensive 203 
gene expression data [53], as well as significant progress in molecular biology, have now opened 204 
the door for a more targeted drug discovery approach, which allows exploitation of defined 205 
pathways and enzymes that are essential for the parasite [53,54]. Better management of the 206 
currently available drugs, with the definition of markers that would allow physicians to stop 207 
treating when the metacestode has actually aborted, might also possibly reduce the duration 208 
and thus individual burden and collective cost of treatment by several years in selected patients 209 
[30,55,56].  210 
 211 
Immunological tools to prevent or treat AE in humans 212 
There is strong evidence for the potential to induce protective immunity against primary 213 
infection with E. multilocularis [57].  As a rough estimate, only 1-10% of exposed/infected 214 
persons will develop disease, while others eliminate the infection due to innate and/or acquired 215 
immunity [40,57,58]. This holds promise for an immunization-based prevention or 216 
immunotherapy of AE.  217 
On the prevention side, vaccine development has a good potential, since it can be assumed that 218 
most resistant persons eliminate infection at the early oncospheral stage, and some at the early 219 
metacestode stage [40]. Large-scale animal experiments in sheep have already demonstrated the 220 
excellent efficacy of vaccination of sheep against E. granulosus infection using the recombinant 221 
antigen EG95 [59]. The same antigen from E. multilocularis is effective in mice [60], and 222 
experimental vaccination studies with defined recombinant proteins such as 14-3-3 protect 223 
against primary (egg) E. multilocularis infection at an even higher degree [61]. This 14-3-3-224 
vaccine has already been applied in a preliminary explorative study in macaques [27]. Therefore, 225 
an anti-AE-vaccine to be applied in humans at risk of infection may become realistic not only 226 
from the scientific point of view, but also in terms of economic considerations. Examples of 227 
other vaccines developed against rather rare but severe and geographically restricted diseases, 228 
such as tick-borne encephalitis in endemic regions in Europe, support this approach [62].  229 
On the treatment side, immunotherapy, i.e. modulating the AE-patient’s immune response, 230 
could be an attractive treatment option. For this, tracing the efficient immune pathways of 231 
infection-resistant persons, and those in immunosuppressed and susceptible patients is required. 232 
Specifically selected candidate-immunomodulating agents such as those tackled by Bardonnet et 233 
al. [30] should be evaluated for their clinical application. 234 
 235 
Concluding remarks 236 
The currently observed trends of E. multilocularis infection in the European fox and dog 237 
populations and the expected increase of annual case numbers of human AE in many areas of 238 
Europe strongly advocate for scaling up research that can improve the fields necessary to yield 239 
better management of this infectious health problem in Europe (Box 1): 240 
• prevention has to be tackled at two specific levels: (a) decreasing or abrogating infection 241 
intensity and extensity in definitive hosts (foxes and dogs) and (b) preventing humans from 242 
contacting E. multilocularis eggs (via contaminated food/water or physical contact with 243 
contaminated surfaces such as e.g. fox and dog fur). Emphasis should be given to (a), as 244 
efficient control at this level automatically renders (b) redundant. 245 
• as long as prevention, as outlined above, cannot be optimally implemented, society has to face 246 
the fact that new clinical cases of AE will occur. Prognosis of AE can be considerably improved 247 
when an early diagnosis and a respectively appropriate treatment option can be offered.  248 
• alternatively, if people e.g. at high exposition risk could be vaccinated against AE, such an 249 
approach might represent an attractive option especially for areas with high infection risk. 250 
From the medical point of view, the focus on developing improved therapeutic tools and 251 
strategies appears as a key requirement, as this is often the only option for handling AE cases. 252 
Nevertheless, other steps should be developed and implemented to rather prevent the disease 253 
from occurring. Thus, a sustainable way to handle the problem of AE clearly requires an 254 
integrated (One-Health) solution. This includes prevention through information campaigns and 255 
education on how to deal with potentially egg-contaminated food (e.g. outdoor-grown 256 
vegetables or berries) as well as with potentially infected pets, and finally personal hygiene for 257 
categories at risk (immune-compromised patients, professionals or people spending a lot of time 258 
outdoor). Surveillance on wild definitive hosts is another element of prevention: monitoring the 259 
existence of hyper-endemicity areas would allow small scale cost-effective campaigns to reduce 260 
the local risk. Finally, it would be interesting to be able to type the haplotype and genotypes of 261 
human infections, and to compare them with the genotype distribution in the sylvatic cycles. 262 
This would help tracking the route of infections and better focusing prevention campaigns. 263 
 264 
 Box 1 Suggested areas of research to be further developed  265 
(i) Design of a systematic, specific, and standardized surveillance of AE in humans and E. 266 
multilocularis infection in animals, to base all further actions on sound epidemiological 267 
data. 268 
(ii)  Improve the management of E. multilocularis infection in definitive hosts (wildlife and 269 
domestic domain). 270 
(iii) Promote earlier diagnosis through improved imaging, immunological and molecular tools.  271 
(iv) Promote accurate treatment assessment and prognostically improved follow-up of AE 272 
patients through improved laboratory and imaging tools, center-based multidisciplinary 273 
care management of AE patients, exploiting experience and approaches developed for 274 
cancer, including psychosocial care, standardized data collection and multicenter clinical 275 
trials.  276 
(v) Development of new therapeutic tools for AE patients through identification and 277 
development of parasitocidal drugs, immunomodulatory interventions and radical curative 278 
surgery.  279 
(vi)  Acquire an novel prevention option for AE in humans through the development of a 280 
infection- or disease-protecting vaccine and be developing a risk group- or area-targeted 281 
vaccination strategy.  282 
________________________________________________________________________________ 283 
 284 
 285 
286 
 286 
REFERENCES 287 
 288 
[1] Eckert, J. et al. (2011) Alveolar echinococcosis (Echinococcus multilocularis) and 289 
neotropical forms of echinococcosis (Echinococcus vogeli and Echinococcus oligarthrus), 290 
pp. 669 – 699. In: Palmer, S. R., Soulsby, L., Torgerson, P.R., Brown, D.W.G., Oxford 291 
Textbook of Zoonoses Biology, Clinical Practice, and Public Health Control. Oxford 292 
University Press. 293 
[2] Romig T (2009) Echinococcus multilocularis in Europe--state of the art. Vet. Res. 294 
Commun. 33, S31 295 
[3] Vuitton, D.A. et al. Clinical epidemiology of human AE in Europe. Vet. Parasitol. (in press). 296 
[4] Böttcher, D. et al. (2013) Diagnostics and epidemiology of alveolar echinococcosis in 297 
slaughtered pigs from large-scale husbandries in Germany. Parasitol. Res. 112, 629-636 298 
[5] Davidson, R.K. et al. (2012) The impact of globalisation on the distribution of 299 
Echinococcus multilocularis. Trends Parasitol. 28,239-247 300 
[6] Rehmann, P. et al. (2003) Echinococcus multilocularis in two lowland gorillas (Gorilla g. 301 
Gorilla). J. Comp. Pathol. 129, 85-88 302 
[7] Wenker, C. et al. (2008) Alveolar echinococcosis – captive lowland gorillas at risk? Proc. 303 
Europ. Ass. Zoo Wildlife Vet. 7, 45-48 304 
[8] Tappe, D. et al. (2007) Echinococcus multilocularis infection of several Old World monkey 305 
species in a breeding enclosure. Am. J. Trop. Med. Hyg. 77, 504-506 306 
[9]  Combes, B. et al. (2012). Westward spread of Echinococcus multilocularis in foxes, 307 
France, 2005-2010. Emerg. Infect. Dis. 18, 2059-2062 308 
[10]  Deplazes, P. et al. (2004) Wilderness in the city: the urbanization of Echinococcus 309 
multilocularis. Trends Parasitol. 20, 77-84 310 
[11] Liccioli S. et al. (in press) Wilderness in the ‘city’ revisited: different urbes shape 311 
transmission of Echinococcus multilocularis by altering predator and prey communities. 312 
Trends Par. 313 
[12] Hegglin, D. et al. (2015) Human-wildlife interactions and zoonotic transmission of 314 
Echinococcus multilocularis. Trends Par. 31, 167-173 315 
[13] Schweiger, A. et al. (2007) Human alveolar echinococcosis after fox population increase, 316 
Switzerland. Emerg. Infect. Dis. 13, 878–882 317 
[14] Schneider, R. et al. (2013) Unexpected increase of alveolar echinococcosis, Austria, 2011. 318 
Emerg. Infect. Dis. 19, 475-477 319 
[15]  Piarroux, M. et al. (2013) FrancEchino Surveillance Network: Populations at risk for 320 
alveolar echinococcosis, France. Emerg. Infect. Dis. 19, 721-728 321 
[16] Said-Ali, Z. et al. (2013) Detecting nested clusters of human alveolar echinococcosis. 322 
Parasitol. 140, 1693-1700 323 
[17] Nahorski, W.L. et al. (2013) Human alveolar echinococcosis in Poland: 1990-2011. PLoS 324 
Negl. Trop. Dis. 7, e1986 325 
[18] Hozáková-Lukácová, L. et al. (2009) Alveolar echinococcosis--a new emerging disease? 326 
Cas. Lek. Cesk. 148, 132-136 327 
[19] Landen, S. et al. (2013) Alveolar echinococcosis in a Belgian urban dweller. Acta 328 
Gastroenterol. Belg. 76, 317-321 329 
[20] Marcinkutė, A., et al. (in press) Echinococcus infections in the Baltic region. Vet. 330 
Parasitol.  331 
[21] Sailer, M. et al. (1997) Alveolar echinococcosis of the liver in a six-year-old girl with 332 
acquired immunodeficiency syndrome. J. Pediat. 130, 320-323 333 
[22] Chauchet, A. et al. & FrancEchino Network (2014) Increased incidence and 334 
characteristics of alveolar echinococcosis in patients with immunosuppression-associated 335 
conditions. Clin. Infect. Dis. 59, 1095-1104 336 
[23]  Vuitton, D.A. et al. (2010) Alveolar echinococcosis: from an incurable rural disease to a 337 
controlled urban infection. Presse Med. 39, 216-230 338 
 [24] Bresson-Hadni, S. et al. (2000) A twenty-year history of alveolar echinococcosis: analysis 339 
of a series of 117 patients from eastern France. Eur. J. Gastroenterol. Hepatol. 12, 327-340 
336 341 
[25] Kern, P. et al. & European Echinococcosis Registry (2003) European echinococcosis 342 
registry: human alveolar echinococcosis, Europe, 1982-2000. Emerg. Infect. Dis. 9, 343-343 
349 344 
[26] Piarroux, M. et al. (2011) Clinical features and evolution of alveolar echinococcosis in 345 
France from 1982 to 2007: results of a survey in 387 patients. J. Hepatol. 55, 1025-1033 346 
[27] Lampe K (2013) Untersuchungen zur Diagnostik und Prophylaxe der alveolären 347 
Echinokokkose bei Makaken. Optimus Verlag, Göttingen [ISBN 978-3-86376-064-9] 348 
[28] Torgerson, P.R. et al. (2008) Alveolar echinococcosis: from a deadly disease to a well-349 
controlled infection. Relative survival and economic analysis in Switzerland over the last 35 350 
years. J. Hepatol. 49, 72-77 351 
[29] Takumi, K. et al. (2012) Mapping the increasing risk of human alveolar echinococcosis in 352 
Limburg, The Netherlands. Epidemiol. Infect. 140, 867-871 353 
[30] Bardonnet, K. et al. (2013) 30-yr course and favorable outcome of alveolar 354 
echinococcosis despite multiple metastatic organ involvement in a non-immune 355 
suppressed patient. Ann. Clin. Microbiol. Antimicrob. 12, 1 356 
[31] Hegglin, D. & Deplazes, P. (2013) Control of Echinococcus multilocularis: Strategies, 357 
feasibility and cost-benefit analyses. Int. J. Parasitol. 43, 327-337. 358 
[32] Deplazes, P. et al. (2011) Role of pet dogs and cats in the transmission of helminthic 359 
zoonoses in Europe, with a focus on echinococcosis and toxocarosis. Vet. Parasitol. 182, 360 
41-53. 361 
[33] Smith, G.C. et al. (2003) Prevalence of zoonotic important parasites in the red fox 362 
(Vulpes vulpes) in Great Britain. Vet. Parasitol. 118, 133-142 363 
[34] Wahlström, H. et al. (2015) Actions taken and future considerations due to the findings 364 
of E. multilocularis in two Scandinavian countries. Vet. Parasitol.  365 
[35] Casulli, A. et al. (2010) Spatial distribution and genetic diversity of Echinococcus 366 
multilocularis in Hungary. Vet. Parasitol. 174, 241-246 367 
[36] Tolnai, Z. et al. (2013) Environmental determinants of the spatial distribution of 368 
Echinococcus multilocularis in Hungary. Vet. Parasitol. 198, 292-297 369 
[37] European Food Safety Authority (EFSA) (2012) The European Union Summary Report on 370 
Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2010. 371 
EFSA Journal 10, 2597 [442 pp.]. http://www.efsa.europa.eu/en/efsajournal/pub/2597.htm 372 
[38] European Centre for Disease Prevention and Control. Annual Epidemiological Report on 373 
Communicable Diseases in Europe 2010. Stockholm: ECDC; 2010. doi 10.2900/35039 374 
[39] Dyachenko, V. et al. (2008) Echinococcus multilocularis infections in domestic dogs and 375 
cats from Germany and other European countries. Vet. Parasitol. 157, 244-253 376 
 [40] Gottstein, B. et al. (2001) Is a high prevalence of Echinococcus multilocularis in wild and 377 
domestic animals associated with increased disease incidence in humans? Emerg. Inf. Dis. 378 
7, 408-412. 379 
[41] Worm control in dogs and cats. ESCCAP Guidelines 01 Second Edition - September 380 
2010. The Mews Studio, Portland Road Malvern, Worcestershire, UK. ISBN 978-1-907259-381 
16-6 382 
[42] Kadry, Z. et al. (2005) Evaluation of treatment and long-term follow-up in patients with 383 
hepatic alveolar echinococcosis. Br. J .Surg. 92, 1110-1116 384 
[43] Bresson-Hadni, S. et al. (2011) Should possible recurrence of disease contraindicate liver 385 
transplantation in patients with end-stage alveolar echinococcosis? A 20-year follow-up 386 
study. Liver Transpl. 17, 855-865 387 
[44] Brunetti, E. et al. & Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis 388 
and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 114, 1-16 389 
[45] Mantion, G.A. &  Vuitton, D.A. (2011) Auto-versus allo-transplantation of the liver for 390 
end-stage alveolar echinococcosis? Chin. Med. J. (Engl). 124, 2803-2805 391 
[46] Kern, P. (2010) Clinical features and treatment of alveolar echinococcosis. Curr. Opin. 392 
Infect. Dis. 23, 505-512 393 
[47] Yang, Y.R. et al. (2005) Brain metastasis of alveolar echinococcosis in a hyperendemic 394 
focus of Echinococcus multilocularis infection. Trans. R. Soc. Trop. Med. Hyg. 99, 937-941 395 
[48] Aurello, P. et al. (2014) Surgical management of microscopic positive resection margin 396 
after gastrectomy for gastric cancer: a systematic review of gastric R1 management. 397 
Anticancer Res. 34, 6283-6288 398 
 [49] Mantion, G.A. & Vuitton, D.A. (2011) Auto-versus allo-transplantation of the liver for 399 
end-stage alveolar echinococcosis? Chin. Med. J. (Engl) 124, 2803-2805 400 
[50] Grenouillet, F. et al. (2010) Human alveolar echinococcosis in France, update 2010. In: 401 
Zoonoses: for an integrated health approach at human-animal interface. Bull. Epidémiol. 402 
Hebdo., Hors-série; 14 septembre 2010 (in French) 403 
http://www.invs.sante.fr/beh/2010/hs/beh_hs.pdf 404 
[51] Jorgensen, P. et al. (2008) Underreporting of human alveolar echinococcosis, Germany. 405 
Emerg. Infect. Dis. 14, 935-937 406 
[52] Hegglin, D. et al. (2008) Survey of public knowledge about Echinococcus multilocularis in 407 
four European countries: need for proactive information. BMC Public Health. 8, 247 408 
[53] Tsai, I.J. et al. (2013) The genomes of four tapeworm species reveal adaptations to 409 
parasitism. Nature 496, 57-63 410 
 [54] Hemphill, A. & Müller, J. (2009) Alveolar and cystic echinococcosis: towards novel 411 
chemotherapeutical treatment options. J. Helminthol. 83, 99-111 412 
[55]  Stumpe, K.D. et al. (2007) F-18-fluorodeoxyglucose (FDG) positron-emission 413 
tomography of Echinococcus multilocularis liver lesions: prospective evaluation of its value 414 
for diagnosis and follow-up during benzimidazole therapy. Infection 35, 11-18 415 
 [56] Caoduro, C. et al. (2013) The role of delayed 18F-FDG PET imaging in the follow-up of 416 
patients with alveolar echinococcosis. J. Nucl. Med. 54, 358-363 417 
 [57] Vuitton, D.A. & Gottstein, B. (2010) Echinococcus multilocularis and its intermediate 418 
host: a model of parasite-host interplay. J. Biomed. Biotechnol. 2010:923193 419 
[58] Vuitton, D.A. et al. (2011) A historical view of alveolar echinococcosis, 160 years after 420 
the discovery of the first case in humans: part 1. What have we learnt on the distribution 421 
of the disease and on its parasitic agent? Chin. Med. J. (Engl) 124, 2943-2953 422 
[59] Gauci, C. et al. (2005) Hydatid disease: vaccinology and development of the EG95 423 
recombinant vaccine. Expert Rev. Vaccines 4, 103 424 
[60] Gauci, C. et al. (2002) Molecular cloning of a vaccine antigen against infection with the 425 
larval stage of Echinococcus multilocularis. Infect. Immun. 70, 3969-3972 426 
[61] Siles-Lucas, M. et al. (2003) The Echinococcus multilocularis 14-3-3 protein protects mice 427 
against primary but not secondary alveolar echinococcosis. Vaccine 21, 431-439 428 
[62] Kollaritsch, H. et al. (2012) Vaccines and vaccination against tick-borne encephalitis. 429 
Expert Rev. Vaccines 11, 1103-1119 430 
[63] Eckert, J. & Deplazes, P. (1999) Alveolar echinococcosis in humans: The current situation 431 
in central Europe and the need for countermeasures. Parasitol. Today 15, 315-319 432 
 433 
434 
 434 
Figure 1. Life cycle of Echinococcus multilocularis. Main definitive host in wildlife is the fox, 435 
and, more recently, in certain areas, the raccoon dog; domestic dogs are also highly susceptible. 436 
Small intestinal parasite load can reach several ten thousands of adult stage worms. Definitive 437 
hosts fecally shed E. multilocularis eggs after a prepatency of at least 28 days. Peroral ingestion 438 
of parasite eggs leads to infection in intermediate hosts (mainly small mammals/rodents), where 439 
the larval stage (metacestode) develops in the liver by formation of a tumour-like tissue, which 440 
consists of a conglomerate of small parasite vesicles. Within fluid-filles vesicles, protoscolices are 441 
formed, which will develop into adult stage worms in the intestine of definitive hosts, following 442 
ingestion of infectious rodents by these. 443 
A: Adult stage fox tapeworm with skolex (head) and proglottids; on the right hand, top view on 444 
a fox intestinal mucosa with plenty of worms. 445 
B: E. multilocularis egg, infectious for intermediate hosts, such as to yield for  the development 446 
of a metacestode tissue in the host liver (indicated by an arrow in the CT picture of a human AE 447 
patient) 448 
C: Protoscoleces, developing in a mature metacestode tissue, represented by the liver lesions in 449 
intermediate hosts. 450 
 451 
 452 
 453 
Figure 2. Approximate distribution of E.  multilocularis in red foxes in Europe. A: Known 454 
distribution in central Europe, status end of 1997 [63]; B: 2015 update: basically according to 455 
Eckert et al. [1] and actualised with information for France by Combes et al. [9]; for Scandinavia 456 
by Wahlström et al. [34], and for the Eastern Baltic region by Marcinkutė et al. [20] 457 
 458 
 459 
